Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc.ANEB · Entity 9617 | Director | April 04, 2025 | April 08, 2025 |
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | Director | May 19, 2017 | May 24, 2017 |
| IMMUNOMEDICS INCIMMU · Entity 145732 | Director | January 08, 2017 | January 10, 2017 |
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director | June 04, 2026 | June 05, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | June 05, 2026 | June 12, 2026 |
| MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770 | 10% owner · See Explanation of Responses | July 16, 2019 | July 18, 2019 |
| NOVELION THERAPEUTICS INC.NVLN · Entity 152369 | Director | May 15, 2017 | May 17, 2017 |
| Orchestra BioMed Holdings, Inc.OBIO · Entity 434 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Anebulo Pharmaceuticals, Inc.
Report date April 04, 2025 · Filed April 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 25,000 |
Reported balance
After 2025-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-04 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2035-04-03 | Direct | 4,964 |
Reported balance
After 2025-04-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-04 · Grant · Acquired 4,964 · Balance 4,964 F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of April 4, 2026 or the date of the 2026 annual meeting of shareholders.
Aralez Pharmaceuticals Inc.
Report date May 19, 2017 · Filed May 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | IndirectBy JALAA Equities, LP | 337,644 |
Reported balance
After 2017-05-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-05-19 · Sale · Disposed 51,041 · Balance 337,644 F1: This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Includes 45,469 shares issued in connection with a previously exercised warrant. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. |
| Common Shares, without par valueSEC Table I · non-derivative | IndirectBy JALAA Equities, LP | 104,176 |
Reported balance
After 2017-05-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-05-22 · Sale · Disposed 233,468 · Balance 104,176 F4: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. |
| Common Shares, without par valueSEC Table I · non-derivative | IndirectBy JALAA Equities, LP | 0 |
Reported balance
After 2017-05-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-05-23 · Sale · Disposed 104,176 · Balance 0 F5: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. |
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
Holding disclosure · report date 2017-05-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 15,000 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Includes 45,469 shares issued in connection with a previously exercised warrant.
F3: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.
F4: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
IMMUNOMEDICS INC
Report date January 08, 2017 · Filed January 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2024-01-08 | Direct | 22,500 |
Reported balance
After 2017-01-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-08 · Grant · Acquired 22,500 · Balance 22,500 |
LIFECORE BIOMEDICAL, INC. \DE\
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,967 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 25,907 · Balance 69,967 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
LIGAND PHARMACEUTICALS INC
Report date June 05, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 107,580 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 836 · Balance 107,580 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. F2: The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records. |
| Common StockSEC Table I · non-derivative | Direct | 107,080 |
Reported balance
After 2026-06-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-06-10 · Sale · Disposed 500 · Balance 107,080 |
| Common StockSEC Table I · non-derivative | Direct | 102,580 |
Reported balance
After 2026-06-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-06-11 · Sale · Disposed 4,500 · Balance 102,580 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $237.00 · Expires 2036-06-05 | Direct | 2,938 |
Reported balance
After 2026-06-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-05 · Grant · Acquired 2,938 · Balance 2,938 F4: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectIndirect | 13,000 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 13,000 F3: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: The total number of shares owned has been reduced by 7,825 shares to reflect a reallocation of the reporting person's shares in accordance with his account records.
F3: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
F4: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
MERRIMACK PHARMACEUTICALS INC
Report date July 16, 2019 · Filed July 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,802 |
Reported balance
After 2019-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-07-16 · Purchase · Acquired 302 · Balance 3,802 F1: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
NOVELION THERAPEUTICS INC.
Report date May 15, 2017 · Filed May 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 242,433 |
Reported balance
After 2017-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-05-15 · Purchase · Acquired 361 · Balance 242,433 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. |
| Common SharesSEC Table I · non-derivative | IndirectBy JALAA Equities, L.P. | 127,491 |
Reported balance
Holding disclosure · report date 2017-05-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 127,491 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. |
| Common SharesSEC Table I · non-derivative | IndirectBy JLV Investments, LP | 6,256 |
Reported balance
Holding disclosure · report date 2017-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,256 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. |
| Common SharesSEC Table I · non-derivative | IndirectBy JLD Investments, L.P. | 16,553 |
Reported balance
Holding disclosure · report date 2017-05-15 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 16,553 F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016.
F2: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest.
Orchestra BioMed Holdings, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2036-06-23 | Direct | 42,553 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 42,553 · Balance 42,553 F1: The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options will vest on the one year anniversary of June 23rd, 2026 (the "Grant Date"), subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2021 Filed Jun 8, 2021 01:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,269 | $0.00 Strike: $115.39 | $0.00 |
DisclosureSEC source: 0000886163-21-000094 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2031-06-04 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 01:39 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 630 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-21-000094 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,664 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,468 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0000886163-20-000080 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,468 Underlying: Common Stock · 2,468 shares Expires 2030-06-10 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 831 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-20-000080 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,034 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 10, 2020. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| September 03, 2019 Filed Sep 4, 2019 23:30 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 750 | $87.01 | $65,257.50 |
DisclosureSEC source: 0000886163-19-000163 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,203 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $86.01 to $88.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 05, 2019 Filed Aug 6, 2019 21:18 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 746 | $90.01 | $67,145.97 |
DisclosureSEC source: 0000886163-19-000145 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,453 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $89.01 to $91.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 31, 2019 Filed Jul 31, 2019 22:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 754 | $93.00 | $70,121.55 |
DisclosureSEC source: 0000886163-19-000132 · edgardoc.xml · nonDerivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,707 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $91.01 to $94.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 22:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 3,000 | $100.22 | $300,662.70 |
DisclosureSEC source: 0000886163-19-000132 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,953 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $95.02 to $105.02, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 250 | $106.01 | $26,502.50 |
DisclosureSEC source: 0000886163-19-000132 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,953 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. Read SEC document |
| July 16, 2019 Filed Jul 18, 2019 23:38 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | PurchaseCommon Stock | 302 | $5.44 | $1,642.88 |
DisclosureSEC source: 0000921895-19-002020 · form412042002_07182019.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · 10% owner · See Explanation of Responses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,802 F1 · security: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 12, 2019 Filed Jul 15, 2019 20:32 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | PurchaseCommon Stock | 1,000 | $5.62 | $5,620.00 |
DisclosureSEC source: 0000921895-19-002005 · form412042002_07152019.xml · nonDerivative · entry 3 Aryeh Jason · CIK 0001376960 · 10% owner · See Explanation of Responses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 F1 · security: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 12, 2019 Filed Jul 15, 2019 20:32 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | PurchaseCommon Stock | 2,400 | $5.71 | $13,704.00 |
DisclosureSEC source: 0000921895-19-002005 · form412042002_07152019.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · 10% owner · See Explanation of Responses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · security: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:32 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | PurchaseCommon Stock | 100 | $5.71 | $571.00 |
DisclosureSEC source: 0000921895-19-002005 · form412042002_07152019.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · 10% owner · See Explanation of Responses 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: The Reporting Person may be deemed to be a member of a Section 13(d) group that collectively beneficially owns more than 10% of the Issuer's outstanding shares of Common Stock. The Reporting Person disclaims beneficial ownership of the securities of the Issuer owned directly by other members of the Section 13(d) group and this report shall not be deemed an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 22:51 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 250 | $107.01 | $26,752.50 |
DisclosureSEC source: 0000886163-19-000115 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,703 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,071 | $0.00 Strike: $113.59 | $0.00 |
DisclosureSEC source: 0000886163-19-000108 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,071 Underlying: Common Stock · 4,071 shares Expires 2029-06-06 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 22:55 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 835 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000108 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,453 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 06, 2019. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 31, 2019 Filed May 31, 2019 22:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 500 | $108.51 | $54,255.00 |
DisclosureSEC source: 0000886163-19-000090 · edgardoc.xml · nonDerivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,618 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.01 to $109.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2019 Filed May 31, 2019 22:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 250 | $110.01 | $27,502.50 |
DisclosureSEC source: 0000886163-19-000090 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,118 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. Read SEC document |
| May 29, 2019 Filed May 31, 2019 22:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 250 | $111.01 | $27,752.50 |
DisclosureSEC source: 0000886163-19-000090 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,868 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. Read SEC document |
| May 20, 2019 Filed May 22, 2019 21:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 250 | $112.01 | $28,002.50 |
DisclosureSEC source: 0000886163-19-000085 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,618 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. Read SEC document |
| May 14, 2019 Filed May 16, 2019 19:54 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 250 | $112.51 | $28,127.50 |
DisclosureSEC source: 0000886163-19-000083 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,368 F1 · shares: The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 17:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 202 | $112.51 | $22,727.02 |
DisclosureSEC source: 0000886163-19-000054 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 51,594 F1 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| August 17, 2018 Filed Aug 17, 2018 23:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 26,862 | $241.81 | $6,495,559.32 |
DisclosureSEC source: 0000886163-18-000123 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 51,392 F1 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 23:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,080 | $245.00 | $264,600.00 |
DisclosureSEC source: 0000886163-18-000123 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 78,254 F1 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $76.77 | $0.00 |
DisclosureSEC source: 0000899243-18-017604 · doc4.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 493 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-017604 · doc4.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,118 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 19, 2018 Filed Jul 3, 2018 22:47 UTC Amendment | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,474 | $0.00 Strike: $195.91 | $0.00 |
DisclosureSEC source: 0000886163-18-000100 · edgardoc.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,474 Underlying: Common Stock · 2,474 shares Expires 2028-06-18 F1 · derivative.exercise_price: This amendment is being filed to correct the exercise price listed in item 2 of Table II in order to reflect the market closing price on the grant date. F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 19, 2018. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| March 09, 2018 Filed Mar 9, 2018 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 4,000 | $176.47 | $705,898.80 |
DisclosureSEC source: 0000886163-18-000046 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 79,334 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.99 to $177.49, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 23:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,500 | $174.88 | $612,095.05 |
DisclosureSEC source: 0000886163-18-000046 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 83,334 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.49 to $175.24, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| February 26, 2018 Filed Feb 27, 2018 23:40 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000028 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,625 F1 · price: Charitable gift to a third party. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:40 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 3,417 | $155.00 | $529,635.00 |
DisclosureSEC source: 0000886163-18-000028 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 86,834 F2 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 22:01 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 24,400 | $140.22 | $3,421,368.00 |
DisclosureSEC source: 0000886163-17-000144 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 90,251 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.15 to $141.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| August 23, 2017 Filed Aug 25, 2017 21:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 2,000 | $127.99 | $255,980.00 |
DisclosureSEC source: 0000886163-17-000108 · wf-form4_150369696228577.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 114,651 F1 · ownership.nature: These securities are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,456 | $113.50 Strike: $113.50 | $278,756.00 |
DisclosureSEC source: 0000886163-17-000070 · edgardoc.xml · derivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,456 Underlying: Common Stock · 2,456 shares Expires 2027-05-25 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:15 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000070 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,625 F1 · shares: Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 25, 2017 Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| May 23, 2017 Filed May 24, 2017 10:07 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 104,176 | $1.41 | $146,877.74 |
DisclosureSEC source: 0001104659-17-034708 · a4.xml · nonDerivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JALAA Equities, LP Disclosed balance after: 0 F5 · price: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. Read SEC document |
| May 22, 2017 Filed May 24, 2017 10:07 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 233,468 | $1.42 | $332,365.04 |
DisclosureSEC source: 0001104659-17-034708 · a4.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JALAA Equities, LP Disclosed balance after: 104,176 F4 · price: This transaction was executed in multiple trades at prices ranging from $1.40 to $1.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. Read SEC document |
| May 19, 2017 Filed May 24, 2017 10:07 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 51,041 | $1.56 | $79,557.61 |
DisclosureSEC source: 0001104659-17-034708 · a4.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JALAA Equities, LP Disclosed balance after: 337,644 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.50 to $1.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 45,469 shares issued in connection with a previously exercised warrant. F3 · ownership.nature: Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP. Read SEC document |
| May 15, 2017 Filed May 17, 2017 17:43 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | PurchaseCommon Shares | 361 | $8.95 | $3,230.95 |
DisclosureSEC source: 0001104659-17-033512 · a4.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,433 F1 · balance_after: Reflects a one-for-five share consolidation of the common shares of the Issuer effective December 16, 2016. Read SEC document |
| May 12, 2017 Filed May 13, 2017 00:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 14,582 | $111.87 | $1,631,333.54 |
DisclosureSEC source: 0000886163-17-000057 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 116,651 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.99 to $112.97, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| May 11, 2017 Filed May 13, 2017 00:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 22,665 | $110.04 | $2,494,024.87 |
DisclosureSEC source: 0000886163-17-000057 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 131,233 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.49 to $111.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:50 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-17-032406 · a4.xml · derivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares, without par value · 15,000 shares Expires 2027-05-11 F4 · derivative.exercise_date: The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:50 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantCommon Shares, without par value | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-032406 · a4.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date. Vested shares will be delivered to the Reporting Person on the earlier of the date that the Reporting Person ceases to provide services to the Board and the date of a Change of Control, as defined in the Issuer's 2016 Amended and Restated Long-Term Incentive Plan, in either case provided that the Restricted Stock Units are vested on such date. F2 · balance_after: Includes 7,500 Common Shares and 7,500 Restricted Stock Units. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 01:30 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 7,000 | $107.58 | $753,060.00 |
DisclosureSEC source: 0000886163-17-000033 · edgardoc.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 153,898 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.49 to $107.94, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 01:30 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 25,000 | $106.00 | $2,650,000.00 |
DisclosureSEC source: 0000886163-17-000033 · edgardoc.xml · nonDerivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Indirect Disclosed balance after: 160,898 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.99 to $106.99, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds. Read SEC document |
| January 08, 2017 Filed Jan 10, 2017 21:10 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Options (right to buy) · Derivative | 22,500 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001104659-17-001800 · a4.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock, par value $0.01 per share · 22,500 shares Expires 2024-01-08 Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 16:12 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantStock Option (Right to Buy) · Derivative | 9,600 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001104659-16-163887 · a4.xml · derivative · entry 1 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 Underlying: Common Shares · 9,600 shares Expires 2026-12-22 F1 · derivative.exercise_price: Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date. F2 · derivative.exercise_date: The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:06 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantCommon Shares, without par value | 82,765 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-160115 · a4.xml · nonDerivative · entry 4 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JLD Investments, L.P. Disclosed balance after: 82,765 F3 · price: Received in exchange for 80,700 shares of Aegerion common stock pursuant to the Merger Agreement. F4 · balance_after: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:06 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantCommon Shares, without par value | 31,280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-160115 · a4.xml · nonDerivative · entry 3 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JLV Investments, LP Disclosed balance after: 31,280 F2 · price: Received in exchange for 30,500 shares of Aegerion common stock pursuant to the Merger Agreement. F4 · balance_after: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:06 UTC | NOVELION THERAPEUTICS INC. NVLN · Entity 152369 | GrantCommon Shares, without par value | 175,979 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-16-160115 · a4.xml · nonDerivative · entry 2 Aryeh Jason · CIK 0001376960 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By JALAA Equities, L.P. Disclosed balance after: 637,457 F1 · price: Received in exchange for 171,587 shares of Aegerion Pharmaceuticals, Inc. ("Aegerion") common stock pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, Aegerion and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into Aegerion, effective November 29, 2016. On the date prior to the effective time of the merger, the closing price of Aegerion's common stock was $1.87 per share and the closing price of the Issuer's common shares was $1.83 per share. F4 · balance_after: The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.